A new study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma.
from Latest Science News -- ScienceDaily https://ift.tt/2XUWP0Y
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment